title: Thalidomide-induced reversible interstitial pneumonitis in a patient with recurrent ovarian cancer.
abstract: BACKGROUND
  Thalidomide is an oral immunomodulatory agent with antiangiogenic properties and activity in ovarian cancer. Pulmonary toxicity unrelated to venous thromboembolism is rare and its etiology is poorly understood.
  
  
  METHODS
  We present the first reported case of reversible drug-induced interstitial lung disease in a patient with recurrent ovarian cancer treated with weekly topotecan and thalidomide. The patient's symptoms and radiographic findings completely resolved upon discontinuing thalidomide while continuing on topotecan.
  
  
  CONCLUSIONS
  Due to its antiangiogenic properties and good tolerance, thalidomide is an attractive agent for the treatment of recurrent ovarian cancer. Gynecologic oncologists and pulmonologists should be aware that acute interstitial lung disease is a possible side effect that appears easily reversible when the drug is stopped.
authors.affiliation: Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
authors.forename: Barbara M
authors.initials: BM
authors.lastname: Buttin
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Moore
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D013792:Thalidomide / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D020533:Angiogenesis Inhibitors; D013792:Thalidomide